Novavax, Inc.

NVAX Healthcare Biotechnology

Novavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024. In the quarter to June 2026, revenue fell 76.3%, EPS fell 148.5%, free cash flow grew 43.0% and total debt rose 31.5%, each against the same quarter a year earlier.

11.26 1.56 −12.17%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−21.7×
Dividend yield
—
F-score
5/9
Altman Z
−2.18
Beneish M
0.39
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(100.06%) (117.16%) 79.70% 323.66%
Piotroski F-Score
5 5 1 1
ROA
23.63% 32.17% (7.52%) (21.62%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
57.55% 78.19% (15.96%) (51.76%)
Average Days of Receivables
11.72 34.58 14.27 16.53
Free Cash Flow per Share
(1.19) (1.56) (0.59) (0.26)
Free Cash Flow
(193.10) (252.05) (96.79) (42.20)
Other line items

Show all line items

Columns are period end dates